| Literature DB >> 24898354 |
Akihiko Kato1, Takako Takita, Hiromichi Kumagai.
Abstract
Entities:
Year: 2014 PMID: 24898354 PMCID: PMC4159493 DOI: 10.1007/s13539-014-0147-9
Source DB: PubMed Journal: J Cachexia Sarcopenia Muscle ISSN: 2190-5991 Impact factor: 12.910
Baseline characteristics according to the baPWV tertile
| Clinical parameters | Male ( | Female ( | ||||
|---|---|---|---|---|---|---|
| 1st tertile (<12.8) | 2nd tertile (12.8 ≤ <14.8) | 3rd tertile (14.8≤) | 1st tertile (<12.2) | 2nd tertile (12.2 ≤ <14.7) | 3rd tertile (14.7≤) | |
| Age (years) | 54 ± 12 | 61 ± 9* | 67 ± 10**# | 55 ± 13 | 62 ± 9* | 70 ± 6**# |
| HD duration (years) | 14 ± 11 | 9 ± 8 | 10 ± 10 | 13 ± 12 | 11 ± 9 | 13 ± 12 |
| Diabetes (%) | 11 | 29 | 36 | 8 | 7 | 23 |
| Creatinine (mg/dL) | 13.6 ± 3.4 | 13.9 ± 2.3 | 12.3 ± 3.1# | 11.1 ± 3.4 | 11.5 ± 1.7 | 9.2 ± 1.7# |
| Albumin (g/dL) | 3.8 ± 0.3 | 3.7 ± 0.2 | 3.6 ± 0.3 | 3.6 ± 0.3 | 3.7 ± 0.3 | 3.6 ± 0.3 |
| Calcium (mg/dL) | 9.0 ± 1.0 | 9.2 ± 0.8 | 9.0 ± 0.9 | 9.3 ± 0.7 | 9.6 ± 0.8 | 8.8 ± 1.0 |
| Phosphorous (mg/dL) | 5.7 ± 1.3 | 6.1 ± 1.4 | 5.6 ± 1.5 | 5.8 ± 2.1 | 5.4 ± 1.9 | 5.2 ± 1.3 |
| hs-CRP (mg/L) | 6.5 ± 23.9 | 8.5 ± 29.8 | 6.6 ± 19.5 | 1.5 ± 2.5 | 4.3 ± 13.2 | 2.3 ± 5.4 |
| Transthyretin (mg/dL) | 33.1 ± 8.6 | 30.2 ± 6.4 | 26.5 ± 7.5** | 27.7 ± 7.5 | 29.0 ± 7.8 | 25.5 ± 7.7 |
| Total cholesterol (mg/dL) | 159 ± 41 | 145 ± 31 | 142 ± 29 | 183 ± 32 | 182 ± 48 | 154 ± 33* |
| HDL-C (mg/dL) | 53 ± 20 | 47 ± 13 | 46 ± 12 | 51 ± 14 | 56 ± 16 | 47 ± 15 |
| Hemoglobin (g/dL) | 11.2 ± 1.3 | 10.5 ± 1.4 | 11.1 ± 1.1 | 11.2 ± 1.1 | 10.5 ± 0.8 | 10.1 ± 1.2 |
| Total lymphocyte count (/μL) | 1320 ± 510 | 1340 ± 530 | 1100 ± 510 | 1440 ± 520 | 1270 ± 510 | 1010 ± 220 |
| BMI (kg/m2) | 20.6 ± 2.8 | 21.9 ± 3.0 | 21.2 ± 2.9 | 19.8 ± 2.7 | 20.1 ± 2.7 | 18.5 ± 1.9 |
| ASFA/BMI | 5.5 ± 2.0 | 6.2 ± 2.3 | 6.0 ± 2.3 | 6.8 ± 2.4 | 8.7 ± 3.7 | 5.5 ± 2.4# |
| AVFA/BMI | 3.6 ± 2.6 | 5.1 ± 3.0 | 4.2 ± 2.8 | 4.2 ± 3.1 | 3.8 ± 2.5 | 1.8 ± 0.9*# |
| TMA/BMI | 10.1 ± 1.9 | 9.8 ± 1.7 | 8.7 ± 2.3* | 7.1 ± 2.0 | 8.7 ± 2.5 | 7.2 ± 1.9 |
| Systolic blood pressure (mmHg) | 120 ± 20 | 142 ± 21** | 161 ± 27**# | 107 ± 26 | 137 ± 20** | 148 ± 21** |
HD hemodialysis, hs-CRP highly sensitive C-reactive protein, HDL-C HDL cholesterol, BMI body mass index, ASFA abdominal subcutaneous fat area, AVFA abdominal visceral fat area, TMA thigh muscle area
*p < 0.05, **p < 0.01 vs. the lowest tertile; #p < 0.05 vs. the middle tertile
Baseline characteristics according to the ABI tertile
| Clinical parameters | Male ( | Female ( | ||||
|---|---|---|---|---|---|---|
| 1st tertile (<1.04) | 2nd tertile (1.04 ≤ <1.14) | 3rd tertile (1.14≤) | 1st tertile (<1.00) | 2nd tertile (1.00 ≤ <1.10) | 3rd tertile (1.10≤) | |
| Age (years) | 64 ± 9 | 63 ± 10 | 55 ± 12** | 69 ± 11 | 59 ± 11* | 59 ± 10* |
| HD duration (years) | 11 ± 10 | 10 ± 9 | 12 ± 10 | 17 ± 13 | 10 ± 10 | 11 ± 9 |
| Diabetes (%) | 30 | 31 | 14 | 8 | 7 | 21 |
| Creatinine (mg/dL) | 12.2 ± 2.4 | 13.8 ± 2.6* | 13.7 ± 3.7 | 10.0 ± 2.3 | 10.8 ± 2.4 | 11.1 ± 3.0 |
| Albumin (g/dL) | 3.6 ± 0.3 | 3.7 ± 0.2 | 3.8 ± 0.3 | 3.5 ± 0.3 | 3.7 ± 0.3 | 3.8 ± 0.3* |
| Calcium (mg/dL) | 8.9 ± 0.9 | 9.0 ± 0.8 | 9.1 ± 1.0 | 9.4 ± 1.1 | 9.1 ± 0.9 | 9.2 ± 0.7 |
| Phosphorous (mg/dL) | 5.6 ± 1.3 | 6.1 ± 1.5 | 5.7 ± 1.4 | 5.1 ± 1.1 | 6.1 ± 2.1 | 5.2 ± 1.7 |
| hs-CRP (mg/L) | 15.2 ± 34.0 | 1.8 ± 2.5 | 5.2 ± 18.2 | 1.0 ± 1.2 | 6.2 ± 13.8 | 0.7 ± 0.7 |
| Transthyretin (mg/dL) | 26.8 ± 6.9 | 29.9 ± 7.3 | 32.3 ± 8.6** | 25.4 ± 5.1 | 26.8 ± 7.6 | 29.9 ± 9.2 |
| Total cholesterol (mg/dL) | 146 ± 26 | 143 ± 43 | 158 ± 33 | 183 ± 41 | 163 ± 30 | 174 ± 48 |
| HDL-C (mg/dL) | 52 ± 19 | 45 ± 14 | 49 ± 12 | 52 ± 11 | 52 ± 18 | 51 ± 16 |
| Hemoglobin (g/dL) | 10.8 ± 1.5 | 10.8 ± 1.2 | 11.2 ± 1.2 | 10.5 ± 0.9 | 10.8 ± 1.1 | 10.5 ± 1.3 |
| Total lymphocyte count (/μL) | 1230 ± 490 | 1190 ± 480 | 1340 ± 580 | 1170 ± 390 | 1300 ± 500 | 1240 ± 510 |
| BMI (kg/m2) | 20.7 ± 2.1 | 21.4 ± 2.7 | 21.5 ± 3.2 | 19.1 ± 2.5 | 19.2 ± 2.7 | 20.1 ± 2.3 |
| ASFA/BMI | 5.7 ± 2.1 | 5.7 ± 2.3 | 6.2 ± 2.2 | 6.9 ± 27 | 6.3 ± 2.7 | 7.8 ± 3.7 |
| AVFA/BMI | 4.0 ± 2.9 | 4.5 ± 2.8 | 4.6 ± 2.9 | 3.7 ± 2.2 | 2.7 ± 2.6 | 3.4 ± 2.8 |
| TMA/BMI | 9.4 ± 2.6 | 9.4 ± 1.8 | 9.7 ± 1.7 | 6.3 ± 2.0 | 8.2 ± 2.0* | 8.3 ± 2.3* |
| Systolic blood pressure (mmHg) | 148 ± 35 | 139 ± 25 | 136 ± 22 | 116 ± 32 | 144 ± 24 | 130 ± 23 |
HD hemodialysis, hs-CRP highly sensitive C-reactive protein, HDL-C HDL cholesterol, BMI body mass index, ASFA abdominal subcutaneous fat area, AVFA abdominal visceral fat area, TMA thigh muscle area
*p < 0.05, **p < 0.01 vs. the lowest tertile
Independent determinants of baPWV and ABI in male and female patients
| Gender | Parameters | Standardized regression coefficient |
|
|
|
|---|---|---|---|---|---|
| 1. baPWV | |||||
| Male | Systolic blood pressure | 40.6 | 63.5 | 0.44 | <0.01 |
| Age | 30.9 | 26.1 | 0.24 | <0.01 | |
| Transthyretin | 44.9 | 11.4 | 0.13 | <0.01− | |
| TMA/BMI ratio | 13.1 | 9.4 | 0.10 | <0.01− | |
| Albumin | 4.1 | 5.0 | 0.06 | 0.03 | |
| Total lymphocyte count | 1895.1 | 4.5 | 0.05 | 0.04− | |
| Total cholesterol | 191.0 | 4.5 | 0.05 | 0.04− | |
| Female | Systolic blood pressure | 56.2 | 17.0 | 0.29 | <0.01 |
| Age | 39.5 | 7.9 | 0.17 | <0.01 | |
| Total lymphocyte count | 2122.4 | 7.1 | 0.16 | 0.01 | |
| AVFA/BMI ratio | 7.8 | 6.3 | 0.12 | 0.02 | |
| Hemoglobin | 12.3 | 4.4 | 0.10 | 0.04 | |
| 2. ABI | |||||
| Male | Transthyretin | 17.6 | 8.6 | 0.05 | 0.04− |
| Female | TMA/BMI ratio | 0.55 | 10.2 | 0.21 | <0.01 |
| Age | 88.3 | 4.9 | 0.11 | 0.03 | |
| Time on hemodialysis | 35.4 | 4.1 | 0.10 | <0.05 | |
We examined the determinants of baPWV and ABI with a stepwise multiple-regression analysis using the 15 parameters (age, time on HD, serum calcium, phosphorous, albumin, total cholesterol, HDL cholesterol, TTR, log-transformed hs-CRP, hemoglobin, total lymphocyte count, systolic blood pressure, AVFA/BMI, ASFA/BMI, and TMA/BMI)
BMI body mass index, AVFA abdominal visceral fat area, TMA thigh muscle area